The new long-term strategy (2025-2035) defines the way – along with the tasks and targets – how Richter plans to navigate for success amidst the loss of exclusivity of cariprazine towards the end of the decade. Richter wants to capitalize on positive trends in the industry and to build on the internal capabilities it created over the last few years. This would allow the company to significantly increase its size, while reducing its environmental footprint, to continue to improve quality of life globally. The 2035 strategy revolves around two strategic pillars. This symbolizes Richter’s ambitions to be a global thought-leader and innovator in some well-defined scientific fields (“Innovative”), while at the same time working hard to make medicines and treatments accessible to an ever-wider range of patients globally (“Affordable”). In Neuropsychiatry, research is underway to find and develop the next blockbuster molecule, while in Women’s Healthcare Richter wants to further build its portfolio of innovative treatments across existing and new therapeutic segments. The biotechnology and generics platforms will constitute a strong base with massive synergy potential to build a competitive and growing Affordable pillar along well-defined therapeutic areas in Europe.
Richter expects to double its WHC revenues as well as its R&D investments and significantly improve its profitability by 2035 by maximizing the potential of the current portfolio and launching innovative products. As thought leaders in women's healthcare, Richter is committed to address unmet medical needs by developing and delivering market-leading solutions in its established therapeutic segments (contraception, fertility, endometriosis and menopause), while also introducing novel therapies in urinary tracts, PCOS and women's oncology. Leveraging its fully integrated value chain with the recently established proprietary research and its ability to embrace external innovation, Richter will also broaden its geographic focus by increasing its presence in the US and strengthen its position in Western Europe.
Richter will focus on maximizing the value of Cariprazine by its loss of exclusivity, while also ensuring CNS remains a value-adding business in the 2030s and 40s. The existing unmet need, the enormous social cost of mental disorders, the ever-increasing demand for treatments (including growing disease awareness) and promising innovations continue to make original research in neuropsychiatry an attractive proposition. Richter will leverage its unparalleled discovery platform and pre-clinical capability, its collaboration with AbbVie and its well-established local ecosystem to build a healthy pipeline of projects and to develop a new molecule with blockbuster potential.
Biosimilars are the fastest growing pharma subsegment – driven by the biological LoEs. The expected multiple product launches and the expanded CDMO capacity will also make Biotech the fastest growing business of Richter with strong double-digit growth through 2035. Key therapeutic area focus includes attractive markets of immunology and musculoskeletal. Richter targets reaching profitable operations by 2027 and will keep on scaling up the business by additional launches (both own developed and in-licensed), ultimately establishing Richter as a solid, reliable biosimilar player. The CDMO business remains a key margin contributor, as Richter continues to provide development and manufacturing services across the full spectrum of biologics.
Richter expects to double its GenMed revenues by 2035, achieve 20%+ Clean EBIT margin much earlier, while significantly increasing its portfolio freshness index to above 15% and raising its R&D spend to 7% of revenues. Large-scale and high-value LoEs (loss of exclusivity) in the relevant therapeutic areas (Cardiovascular, traditional CNS, Blood Therapies and Diabetes/Obesity) create attractive growth prospects (6% generics market CAGR in 2025-35 in Europe despite prevailing price erosion) in the short- and medium-term alike. Operational excellence in core regions combined with synergies between small and large molecule capabilities will enable Richter to expand its geographic reach into Western Europe and deliver integrated therapeutic solutions for patients and healthcare providers.